Back to Newsroom

CombiMatrix featured in Genetic Engineering and Biotechnology News

Honing Prenatal Screening Tests

Genetic testing of cell-free fetal DNA moves the bar on screening accuracy.

Prenatal screening for Down syndrome first became available for expectant mothers with the advent, in the late 1960s, of a diagnostic test employing amniocentesis and fetal karyotyping. At the time, only one risk factor was considered—the age of the mother.

In the ensuing years, discoveries showing the correlation between over- and under-expression of specific biomarkers in the mother’s blood, such as alpha-fetoprotein (AFP), human chorionic gonadotropin (hCG), estriol, and inhibin A, led to new prenatal screening tests that could indicate the likelihood of not only Down syndrome but other potential birth defects.

Click here to read the full aritcle